Phathom Pharmaceuticals, Inc. Issuance/Purchase of Shares

Issuance/Purchase of Shares of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Issuance/Purchase of Shares growth rates and interactive chart.


Highlights and Quick Summary

  • Issuance/Purchase of Shares for the quarter ending September 29, 2021 was $1.27 Million (a 1116.35% increase compared to previous quarter)
  • Year-over-year quarterly Issuance/Purchase of Shares decreased by -98.59%
  • Annual Issuance/Purchase of Shares for 2020 was $89.5 Million (a -53.28% decrease from previous year)
  • Annual Issuance/Purchase of Shares for 2019 was $191 Million (a 9573500.0% increase from previous year)
  • Twelve month Issuance/Purchase of Shares ending September 29, 2021 was $91.2 Million (a -67.73% decrease compared to previous quarter)
  • Twelve month trailing Issuance/Purchase of Shares decreased by -67.52% year-over-year
Trailing Issuance/Purchase of Shares for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$91.2 Million $283 Million $281 Million $281 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Issuance/Purchase of Shares of Phathom Pharmaceuticals, Inc.

Most recent Issuance/Purchase of Sharesof PHAT including historical data for past 10 years.

Interactive Chart of Issuance/Purchase of Shares of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Issuance/Purchase of Shares for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1.27 $0.1 $0.41
2020 $89.46 $89.46
2019 $192.77 $-1.3 $191.47
2018 $0.0 $0.0 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.